Article (Scientific journals)
Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
De Greef, E.; Hoffman, I.; D'Haens, G. et al.
2012In Acta Gastro-Enterologica Belgica, 75 (4), p. 425-31
Peer Reviewed verified by ORBi
 

Files


Full Text
2012-Safety and cost of infliximab for... pediatric patients... Crhon's disease-Acta Gast Belg-PostPE.pdf
Publisher postprint (172.03 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
De Greef, E.
Hoffman, I.
D'Haens, G.
Van Biervliet, S.
Smets, F.
Scaillon, M.
Dewit, O
Peeters, H.
Paquot, I.
Alliet, P.
Arts, W.
Hauser, B.
Vermeire, S.
Van Gossum, A.
Rahier, Jean-François
Etienne, I.
Louis, Edouard  ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Coche, J. C.
Mahachie John, Jestinah ;  Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Van Steen, Kristel  ;  Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Veereman, G.
More authors (11 more) Less
Language :
English
Title :
Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
Publication date :
2012
Journal title :
Acta Gastro-Enterologica Belgica
ISSN :
0001-5644
eISSN :
1784-3227
Publisher :
Acta Medica Belgica, Bruxelles, Belgium
Volume :
75
Issue :
4
Pages :
425-31
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 March 2013

Statistics


Number of views
84 (12 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
3

Bibliography


Similar publications



Contact ORBi